Lo Y M, Chan L Y, Lo K W, Leung S F, Zhang J, Chan A T, Lee J C, Hjelm N M, Johnson P J, Huang D P
Department of Chemical Pathology, The Chinese University of Hong Kong, New Territories, Hong Kong Special Administrative Region.
Cancer Res. 1999 Mar 15;59(6):1188-91.
Using real-time quantitative PCR, cell-free EBV DNA was detectable in the plasma of 96% (55 of 57) of nasopharyngeal carcinoma (NPC) patients (median concentration, 21058 copies/ml) and 7% (3 of 43) of controls (median concentration, 0 copies/ml). Advanced-stage NPC patients had higher plasma EBV DNA levels than those with early-stage disease. At 1 month after completion of radiotherapy, plasma EBV DNA was undetectable in 7 of 15 subjects (47%) but remained high in the remaining 8 subjects (53%). Clinical examination revealed that all of the former seven subjects had complete tumor regression, whereas six of the eight latter subjects exhibited evidence of disease persistence or had developed distant metastases. These results suggest that quantitative analysis of plasma EBV DNA may be a useful clinical and research tool in the screening and monitoring of NPC patients.
采用实时定量聚合酶链反应，在96%（57例中的55例）的鼻咽癌（NPC）患者血浆中可检测到游离EBV DNA（中位浓度为21058拷贝/毫升），而在7%（43例中的3例）的对照者血浆中可检测到（中位浓度为0拷贝/毫升）。晚期NPC患者的血浆EBV DNA水平高于早期患者。放疗结束1个月后，15名受试者中有7名（47%）血浆EBV DNA检测不到，但其余8名受试者（53%）的血浆EBV DNA水平仍很高。临床检查显示，前7名受试者的肿瘤均完全消退，而后8名受试者中有6名有疾病持续存在的证据或已发生远处转移。这些结果表明，血浆EBV DNA定量分析可能是筛查和监测NPC患者的一种有用的临床和研究工具。
